Havrix Junior is a medicine containing the active ingredient(s) hepatitis a vaccine. On this page you will find out more about Havrix Junior, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: hepatitis a vaccine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Havrix Junior 720 ELISA units/0.5 mL injection suspension, 0.5 mL vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
HAVRIX is indicated for active immunisation against hepatitis A virus (HAV) infection in susceptible subjects at risk of exposure to HAV. HAVRIX JUNIOR is indicated in subjects aged 2 to 15 years and HAVRIX 1440 is indicated in subjects aged 16 years and older. In areas of low prevalence of hepatitis A, immunisation with HAVRIX is particularly recommended in the following subjects: Travellers : Persons travelling to areas of intermediate or high endemicity for hepatitis A. These areas include Africa, Asia, India, the Pacific Islands, the Mediterranean basin, the Middle East, Central and South America. Armed Forces : Armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of HAV infection. Persons for whom hepatitis A is an occupational hazard or for whom there is an increased risk of transmission. These include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote Aboriginal and Torres Strait Islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. Homosexual men : Increased incidence of hepatitis A infection among homosexual males suggests that the disease may be sexually transmitted in this group. Contacts of infected persons : Since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. The use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. Specific population groups known to have a higher incidence of hepatitis A: eg. Australian aboriginals, recognised community-wide HAV epidemics. Individuals with chronic liver disease and recipients of liver transplants, as hepatitis A infections is likely to be more severe in these groups. Many injecting drug users will have pre-existing liver disease from hepatitis B or hepatitis C infection. Recipients of blood products, such as Factor VIII eg. haemophiliacs. HAVRIX will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E or other pathogens known to infect the liver.
Table of characteristics
|Visual appearance||A turbid liquid with a slow settling white deposit.|
|Dosage Form||Injection, suspension|
|Route of administration||Intramuscular|
1 X 0.5mL: Prescription Only Medicine, or Prescription Animal Remedy
10 x 0.5mL: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Do not Freeze|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
Havrix 1440 Preservative Free Suspension for injection - myDr.com.au
Havrix 1440 Preservative Free Suspension for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 0 results